{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:32:40Z","timestamp":1794342760872,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.vaccine.2024.126535","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:04:02Z","timestamp":1733519042000},"page":"126535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening"],"prefix":"10.1016","volume":"46","author":[{"given":"Chenoa","family":"Sankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marione","family":"Sch\u00f6nfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Sekiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseera","family":"Pickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Mubaiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dini","family":"Mawela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sipho","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Bamford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohlang","family":"Sehloho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrigan","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0005","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta bio medica: Atenei parmensis"},{"key":"10.1016\/j.vaccine.2024.126535_bb0010","author":"South African Health Products Regulatory Authority"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126535_bb0015","first-page":"17","volume":"93","year":"2018"},{"key":"10.1016\/j.vaccine.2024.126535_bb0020","series-title":"EPI Disease Surveillance Guideline. Guidelines for Detecting, Reporting, Investigation and Responding to EPI Priority Diseases","author":"Department of Health","year":"2015"},{"key":"10.1016\/j.vaccine.2024.126535_bb0025","series-title":"COVID-19 vaccines: Safety surveillance manual","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.vaccine.2024.126535_bb0030","series-title":"Global vaccine safety blueprint 2.0 (GVSB2.0) 2021\u20132023","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126535_bb0035","series-title":"World Health Organization. Vaccine safety basics: learning manual","author":"Mort","year":"2013"},{"key":"10.1016\/j.vaccine.2024.126535_bb0040","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7015a2","article-title":"Progress in immunization safety monitoring\u2014worldwide, 2010\u20132019","volume":"70","author":"Salman","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.126535_bb0045","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7249a2","article-title":"Progress in immunization safety monitoring\u2014worldwide, 2020\u20132022","volume":"72","author":"Blau","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"03","key":"10.1016\/j.vaccine.2024.126535_bb0050","first-page":"13","volume":"96","author":"mondiale de la Sant\u00e9 O, World Health Organization","year":"2021","journal-title":"WHO"},{"key":"10.1016\/j.vaccine.2024.126535_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.891954","article-title":"A qualitative study of stakeholders\u2019 views on pharmacovigilance system, policy, and coordination in Pakistan","volume":"13","author":"Khan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2024.126535_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.789103","article-title":"Assessment of the current state of pharmacovigilance system in Pakistan using indicator-based assessment tool","volume":"12","author":"Khan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2024.126535_bb0065","article-title":"Leveraging COVID-19 vaccine safety monitoring in Ethiopia and Pakistan to enhance system-wide safety surveillance","volume":"12","author":"Hagos","year":"2024","journal-title":"Global Health: Sci Practice"},{"key":"10.1016\/j.vaccine.2024.126535_bb0070","series-title":"WHO global benchmarking tool (GBT) for evaluation of national regulatory systems of medical products: Revision VI","author":"World Health Organization (WHO)","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126535_bb0075","series-title":"List of national regulatory authorities (NRAS) operating at maturity level 3 and maturity level 4","author":"World Health Organization (WHO)","year":"2023"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0080","first-page":"e3663","article-title":"Surveillance System Evaluation for COVID-19 Vaccine\u2013Associated Adverse Events Following Immunization (AEFI), Sindh Pakistan","volume":"8","author":"Qureshi","year":"2021","journal-title":"Iproc 2022"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0085","first-page":"e36514","article-title":"Evaluation of the National Electronic Disease Surveillance System amid the COVID-19 pandemic in Elsahel District, Cairo Governorate, Egypt","volume":"vol. 8","author":"Girgis","year":"2020","journal-title":"Iproc 2022"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0090","first-page":"e36584","article-title":"Evaluation of the dengue surveillance system in Khyber Pakhtunkhwa Province, Pakistan, in","volume":"vol. 8","author":"Khan","year":"2020","journal-title":"Iproc 2022"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0095","article-title":"Evaluation of the Dengue Surveillance System in Islamabad","volume":"8","author":"Saeed","year":"2019","journal-title":"Iproc 2022"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0100","first-page":"e36595","article-title":"Evaluation of the Leishmania surveillance system, Yemen","volume":"vol. 8","author":"Aldaeri","year":"2021","journal-title":"Iproc 2022"},{"issue":"27","key":"10.1016\/j.vaccine.2024.126535_bb0105","first-page":"55","article-title":"Evaluation of the adverse drug reaction surveillance system Kadoma City, Zimbabwe 2015","volume":"24","author":"Muringazuva","year":"2017","journal-title":"Pan Afr Med J"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0110","doi-asserted-by":"crossref","first-page":"1360560","DOI":"10.1080\/16549716.2017.1360560","article-title":"Evaluating the electronic tuberculosis register surveillance system in Eden District, Western cape, South Africa, 2015","volume":"10","author":"Mlotshwa","year":"2017","journal-title":"Glob Health Action"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126535_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120226","article-title":"Evaluation of two influenza surveillance systems in South Africa","volume":"10","author":"Budgell","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.126535_bb0120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijid.2017.03.022","article-title":"Evaluation of the notifiable disease surveillance system in South Africa","volume":"59","author":"Girdler-Brown","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126535_bb0125","first-page":"1","article-title":"Guidelines working group Centers for Disease Control and Prevention (CDC). Updated guidelines for evaluating public health surveillance systems: recommendations from the guidelines working group","volume":"50","author":"German","year":"2001","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2024.126535_bb0130","series-title":"Standard Operational Procedure (SOP) for Adverse Events Following Immunisation (AEFI) for COVID-19 vaccinations","author":"Western Cape Department of Health CDC-EPI","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126535_bb0135","series-title":"Causality assessment of an adverse event following immunization (AEFI): User manual for the revised WHO classification","author":"World Health Organization","year":"2013"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126535_bb0140","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/nhs.12048","article-title":"Content analysis and thematic analysis: implications for conducting a qualitative descriptive study","volume":"15","author":"Vaismoradi","year":"2013","journal-title":"Nurs Health Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0145","article-title":"Evaluation of the adverse events following immunizations surveillance system in Harare City, Zimbabwe, 2016: a descriptive cross sectional study","volume":"28","author":"Zvanaka","year":"2017","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.vaccine.2024.126535_bb0150","series-title":"An evaluation of the adverse events following immunization surveillance system: A case of the Oral cholera vaccine mass campaign","author":"Gadzayi","year":"2019"},{"key":"10.1016\/j.vaccine.2024.126535_bb0155","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1186\/s12889-019-7482-x","article-title":"Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase from 1997 to 2017","volume":"19","author":"Masuka","year":"2019","journal-title":"BMC Public Health"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126535_bb0160","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/14740338.2024.2387322","article-title":"Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches","volume":"23","author":"Peter","year":"2024","journal-title":"Expert Opinion on Drug Safety"},{"issue":"25","key":"10.1016\/j.vaccine.2024.126535_bb0165","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.vaccine.2023.04.055","article-title":"Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future","volume":"41","author":"Black","year":"2023","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2024.126535_bb0170","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1016\/j.vaccine.2022.04.103","article-title":"A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: a Canadian immunization research network study","volume":"40","author":"Psihogios","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126535_bb0175","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1017\/S0950268811002160","article-title":"Evaluation of animal and public health surveillance systems: a systematic review","volume":"140","author":"Drewe","year":"2012","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2024.126535_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-015-1791-5","article-title":"Surveillance systems evaluation: a systematic review of the existing approaches","volume":"15","author":"Calba","year":"2015","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126535_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-publhealth-031816-044348","article-title":"Public health surveillance systems: recent advances in their use and evaluation","volume":"38","author":"Groseclose","year":"2017","journal-title":"Annu Rev Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T16:30:33Z","timestamp":1737304233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24012179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"alternative-id":["S0264410X24012179"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126535","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126535"}}